REG - GENinCode PLC - NHS implementation of Lipid inCode testing

GenincodeAnnouncement

26/07/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220726:nRSZ6856Ta&default-theme=true

RNS Number : 6856T  GENinCode PLC  26 July 2022

GENinCode Plc

("GENinCode" or the "Company")

 

NHS implementation of Lipid inCode® testing of patients suffering with
hypercholesterolemia and familial hypercholesterolemia

Lipid inCode® becomes the first commercial polygenic test for CVD to be
implemented by the NHS

 

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused
on the prevention of cardiovascular disease, announces the expansion of its
collaboration with the Academic Health Science Network for the North East and
North Cumbria ("AHSN NENC") to implement the use of its Lipid inCode® test in
the AHSN NENC Primary Care Network (PCN) for the diagnosis of
hypercholesterolemia (high levels of cholesterol) and familial
hypercholesterolemia ("FH"). This marks the introduction of GENinCode's first
UK polygenic product aimed at improving the diagnosis and treatment of
hypercholesterolemia and preventing the onset of cardiovascular disease
("CVD").

There are 15 Academic Health Science Networks ("AHSN") across England,
established by NHS England in 2013 to spread innovation at pace and scale -
improving health and generating economic growth. Each AHSN works across a
distinct geography serving a different population in each region. The AHSN
NENC leads a national AHSN programme
(https://www.ahsnnetwork.com/about-academic-health-science-networks/national-programmes-priorities/lipid-management-and-fh)
aimed at identification of FH and lipid management, in collaboration with the
Accelerated Access Collaborative (AAC) and the National Institute for Health
& Care Excellence (NICE).

 

The NHS implementation of Lipid inCode® marks the introduction of GENinCode's
first UK genetic product aimed at improving the diagnosis and treatment of
familial hypercholesterolemia and preventing the onset of cardiovascular
disease ("CVD"). Lipid inCode® is the first commercial polygenic test for CVD
to be implemented by the NHS.

 

Following the positive results of its Lipid inCode® NHS clinical study(1) and
recent successful completion of the Lipid inCode® AHSN NENC pilot, the AHSN
NENC will now implement the use of Lipid inCode® in the Darlington PCN and
community practice representing over 100,000 patients in the North of England.
Within this population, Lipid inCode will detect and diagnose people with high
cholesterol, a known important risk factor for the development of CVD.
Improved detection supports better treatment and preventative care. Lipid
inCode® offers genetic testing for the causes of high cholesterol, with rapid
results and comprehensive reporting for clinicians. Lipid inCode® will be
offered at a reduced cost to the NHS, to help support the ambition it declared
in its Long Term Plan to detect 25% of people with FH by 2024.

 

In the UK around 7.6m people live with heart and circulatory disease, which
causes 25% of all deaths annually in the UK. CVD can be reduced by identifying
and treating individuals at risk, and the NHS 10 Year Plan (2019) sets out
significant ambitions to address the CVD prevention, including identifying
individuals with hypercholesterolemia and particularly those with FH.

 

FH is an inherited monogenic condition which affects an individual's ability
to regulate and remove cholesterol from their blood. FH affects approximately
one in 250 people in the UK population and globally. The NHS Long Term Plan
sets out to expand access to genetic testing for FH, which causes early heart
attacks and sudden cardiac death. Individuals suffering with FH have a higher
risk of heart disease and death at a younger age. For individuals suffering
with FH it is important to lower their cholesterol to healthy levels as early
in life as possible, often requiring medicines such as statins or more
aggressive treatment to help better control cholesterol levels.

 

CVD is a broad disease classification which encompasses conditions such as
coronary artery disease (causing angina, heart attacks, heart failure),
cerebrovascular disease (causing stroke, and some dementia), peripheral
vascular disease (causing limb ischemia, and some chronic kidney disease) and
venous thromboembolism. CVD is the leading cause of death and disability
worldwide accounting for one in every four deaths in the United States.
According to the US National Institutes of Health (NIH), by 2030, the global
cost of CVD is set to rise to US$1,044 billion, from approximately US$863
billion in 2010, and is both a major health issue and global economic burden.

 

GENinCode has a vision to assist clinicians and inform patients in
interpreting cardiovascular risk, and to improve public health using the
predictive capability of genomics. High genetic risk patients are assisted in
making lifestyle choices and can receive targeted treatment to improve
outcomes. Over the past 15 years GENinCode has made a substantial investment
in its research, bioinformatic data, technology, and product development to
assess disease risk, in order to help clinicians and patients prevent the
onset of CVD.

 

Matthew Walls, CEO of GENinCode PLC said: "The collaboration with the AHSN
NENC continues to advance our Lipid inCode test to identify patients at high
risk of heart disease and stroke representing the largest cause of death in
the UK. The implementation of Lipid inCode marks the beginning of our NHS
diagnostic testing for hypercholesterolemia and familial hypercholesterolemia
sufferers and we look forward to supporting the NHS in reaching its long term
plan to diagnose patients with hypercholesterolemia."

 

Professor Julia Newton, Medical Director at AHSN NENC commented: "We are
delighted to now move into the implementation phase for Lipid inCode® to
advance the diagnosis and treatment of hypercholesterolemia and familial
hypercholesterolemia. With the added benefit of easy sample collection,
improved test turnaround times at a reduced costs to the NHS, we can start to
deliver the Lipid inCode test in our primary care practice and welcome this
approach to help support and deliver the NHS 10-Year plan to reduce the onset
of cardiovascular disease."

 

For more information visit www.genincode.com (http://www.genincode.com)

Enquiries:

 

 GENinCode Plc                          www.genincode.com (http://www.genincode.com) or via Walbrook PR
 Matthew Walls, CEO
 Paul Foulger, CFO

 Stifel Nicolaus Europe Limited (Nomad and Joint Broker)                                    Tel: +44 (0)20 7710 7600
 Alex Price / Ben Maddison / Richard Short

 Cenkos Securities Plc (Joint Broker)   Tel: +44 (0)20 7397 8900
 Giles Balleny
 Dale Bellis / Michael Johnson (Sales)

 Walbrook PR Limited                                              Tel: 020 7933 8780 or genincode@walbrookpr.com

 Anna Dunphy / Paul McManus / Louis Ashe-Jepson

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of
cardiovascular disease. Cardiovascular disease is the leading cause of death
and disability worldwide.

 

GENinCode operates business units in the UK, Europe through GENinCode S.L.U,
and in the United States through GENinCode U.S. Inc.

 

GENinCode predictive technology provides patients and physicians with globally
leading preventative care and treatment strategies. GENinCode CE marked
invitro-diagnostic molecular tests combine clinical algorithms and
bioinformatics to provide advanced patient risk assessment to predict disease
onset.

 

About Academic Health Science Network for the North East and North Cumbria
(AHSN NENC):

The AHSN NENC is focused on building and maintaining strong relationships and
partnerships which is fundamental to its success. Member organisations and
stakeholders include NHS, academia and industry partners in the North East and
North Cumbria.

By developing and maintaining strong relationships with members and
practitioners, the Network continually shares knowledge and translates ideas
into practice. The Network benefits from harnessing the expertise and
experience of clinical staff, for example, to act as change agents to adopt
and diffuse new practice across organisations and support the research
community to develop knowledge.

 

 

To deliver against what is a broad remit, the Network works in close
collaboration with The AHSN Network (http://www.ahsnnetwork.com/)  across
the UK as well as with other national organisations, such as NIHR Clinical
Research Network
(https://www.nihr.ac.uk/nihr-in-your-area/north-east-and-north-cumbria/) .
Other partnerships are developed where appropriate, for example, with the
third sector and with industry.

About Cardiovascular Disease (CVD):

Heart and circulatory disease, also known as cardiovascular disease, causes a
quarter of all deaths in the UK and is the largest cause of premature
mortality in deprived areas and is the single biggest area where the NHS can
save lives over the next 10 years. CVD is largely preventable, through
lifestyle changes and a combination of public health and NHS action on smoking
and tobacco addiction, obesity, tackling alcohol misuse and food
reformulation.

Early detection and treatment of CVD can help patients live longer, healthier
lives. Many people are still living with undetected, high-risk conditions such
as high blood pressure, raised cholesterol, and atrial fibrillation (AF).
Progress continues in the NHS to identify and diagnose people routinely
knowing their 'ABC' (AF, Blood pressure and Cholesterol).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBELLLLDLLBBE